Listed by the USPTO as STONEBRAKER, ALYSSA RAE
Tech Center 1600 • Art Units: 1600 1627 1642 1644 1671
This examiner grants 59% of resolved cases
STONEBRAKER, ALYSSA RAE is assigned to Tech Center 1600 and Art Unit 1600. Her profile covers 112 resolved cases, with an allowance rate of 58.9%. Interviews show a 49.4% lift, and the median time to allowance is 1249 days. The reported relationship between interviews and outcomes is substantial, while the median duration indicates a lengthy path to allowance.
The leading companies are Regeneron Pharmaceuticals Inc., Genentech Inc., and Merck Sharp & Dohme LLC. The firms are MERCHANT & GOULD P.C., Fox Rothschild, LLP, and Adams & Reese LH. Applicants can prioritize clear interview objectives and prepare for continued prosecution, while recognizing that the limited record constrains broad forecasting.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | Final Rejection | Genentech, Inc. |
| 18497352 | METHODS OF TREATING CANCER WITH A COMBINATION OF ADOPTIVE CELL THERAPY AND A TARGETED IMMUNOCYTOKINE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18133288 | COMPOSITIONS AND METHODS FOR UNIVERSAL TUMOR CELL KILLING | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17281025 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Final Rejection | NORTH CAROLINA STATE UNIVERSITY |
| 18287539 | Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation | Non-Final OA | Northeastern University |
| 18354436 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | Non-Final OA | Ajinomoto Co., Inc. |
| 17498521 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | Non-Final OA | University of Leicester |
| 18692037 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | Non-Final OA | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.9% of resolved applications examined by Alyssa Rae Stonebraker were allowed (112 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +49.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Alyssa Rae Stonebraker took 1,249 days on average from filing to allowance.
Alyssa Rae Stonebraker examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
